A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 395,875 shares of JANX stock, worth $19.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
395,875
Previous 136,430 190.17%
Holding current value
$19.4 Million
Previous $5.72 Million 214.68%
% of portfolio
0.05%
Previous 0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$35.29 - $50.26 $9.16 Million - $13 Million
259,445 Added 190.17%
395,875 $18 Million
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $4.79 Million - $8.84 Million
136,430 New
136,430 $5.72 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.04B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.